NinePoint Medical, Inc., a Cambridge, Mass.-based developer of in vivo pathology devices, has completed a $33m Series A financing.
The round was led by Third Rock Ventures and Prospect Venture Partners.
The financing will allow the company to develop its innovative in vivo pathology technology platform, which will be used to commercialize a portfolio of medical devices for the examination of dysplastic, pre-cancerous and cancerous cells.
The initial focus will be on developing devices for the examination of the gastrointestinal tract.
NinePoint also plans to expand its team with approximately 25 new hires over the next 12 months and to run a manufacturing facility at its Cambridge headquarters.